Additional file 6: of Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review

Figure S6. List and frequency distribution of studies employing the use of genetically modified stem cells (GM-MSC) of human adipose tissue (AT), bone marrow (BM), and fetal umbilical cord (UC) matrix origin. In each row of the table, the length of black-gradient filled horizontal bars is proportional to the total number of studies (value within bar) relevant to specific GM-MSC/tumor combinations; the list of respective citations is shown under the bars. Cancer types are ranked in descending order of world incidence (see also Fig. 2). Only tumors whose use is described by three or more independent studies are shown. Arrows at the beginning of each row of the table symbolize deviation of the frequency of tumor targeted in experimental cytotherapy work from their respective incidence/frequency of occurrence globally (yellow = difference within 5%; green, up = difference > 5% in favor of cytotherapy—tumor over-representation; red, down = difference of > 5% in favor of incidence—tumor under-representation). */**/# Studies referring to cervical cancer/ ovarian cancer/ use of UC-blood MSC, respectively. (TIF 9450 kb